New approaches to fight serious diseases
VBL Therapeutics is a clinical-stage biotechnology company using its unique scientific platforms and drug development capabilities to fight immune-inflammatory diseases and cancer. Because these serious and sometimes life-threatening diseases are inadequately addressed by current therapies, VBL is committed to developing novel treatments that address this unmet need.
Novel technology, promising therapies
VBL Therapeutics pioneered the Lecinoxoid class of oral anti-inflammatory agents, currently in a Phase 2 clinical trial for the treatment of psoriasis. We have also developed an innovative, proprietary platform technology, VTS™ (Vascular Targeting System). We have used this technology to develop promising therapeutic compounds for cancer and ischemic diseases. VB-111, our lead oncology drug candidate, is in Phase 2 clinical development in patients with thyroid cancer and glioblastoma.
Making an impact for patients in the clinic
Our first-in-class compound, VB-201 has completed Phase 2 clinical development for the treatment of psoriasis and inflammation in atherosclerosis. VBL has also entered Phase 2 clinical development with VB-111, the company’s lead oncology drug candidate, in thyroid cancer and glioblastoma.